Aurdan Capital Management LLC cut its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 33.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 404 shares of the company’s stock after selling 202 shares during the period. Aurdan Capital Management LLC’s holdings in Eli Lilly and Company were worth $334,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Garner Asset Management Corp lifted its holdings in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock valued at $411,000 after purchasing an additional 12 shares in the last quarter. Brighton Jones LLC boosted its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Orion Capital Management LLC boosted its holdings in Eli Lilly and Company by 2.5% in the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company’s stock worth $1,243,000 after purchasing an additional 40 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG boosted its holdings in Eli Lilly and Company by 4.1% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company’s stock worth $49,993,000 after purchasing an additional 2,568 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Price Performance
Shares of Eli Lilly and Company stock opened at $787.00 on Thursday. The stock’s 50-day simple moving average is $767.12 and its 200-day simple moving average is $800.05. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a market capitalization of $745.87 billion, a price-to-earnings ratio of 64.04, a PEG ratio of 1.14 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.
Eli Lilly and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company’s dividend payout ratio is 48.82%.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on LLY. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. Finally, HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.61.
Check Out Our Latest Analysis on LLY
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- Dividend Payout Ratio Calculator
- Buffett’s $2B+ Bet With Big Long-Term Potential Just Got Upgraded
- How Technical Indicators Can Help You Find Oversold StocksĀ
- AI Chip Arms Race: 3 Must-Watch Equipment Stocks
- ESG Stocks, What Investors Should Know
- Will Oracle’s Cloud and AI Deals Propel It to New Highs?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.